Valuation and Timelines, page-10

I would also think that if Edwards lost the vast majority of their revenue
through having AVR take their sales through a vastly superior valve, that
investors would greatly mark down the value of Edwards shares. They can't afford to risk
this.

I think the market share that AVR will capture will eventually be much higher than 40%
If patients are given the information that they have a choice of two different valves,
one of which will make them feel much fitter and will last them a lifetime versus another
which will just enable them to get by and will maybe only last 3-5 yrs I am pretty sure
the vast majority will opt for the first option.